% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Teleanu:301718,
      author       = {M.-V. Teleanu$^*$ and A. Schneider$^*$ and C. Ball$^*$ and
                      M. F. Leber$^*$ and C. Stange$^*$ and E.
                      Krieghoff-Henning$^*$ and K. Beck$^*$ and C. E. Heilig$^*$
                      and S. Kreutzfeldt$^*$ and B. Kuster$^*$ and D. Lipka$^*$
                      and S. Fröhling$^*$},
      title        = {{C}elebrating {U}lrik {R}ingborg: {M}ulti-{O}mics-{B}ased
                      {P}atient {S}tratification for {P}recision {C}ancer
                      {T}reatment.},
      journal      = {Biomolecules},
      volume       = {15},
      number       = {5},
      issn         = {2218-273X},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2025-01110},
      pages        = {693},
      year         = {2025},
      note         = {#EA:B340#LA:B340# / 2025 May 10;15(5):693},
      abstract     = {Precision oncology is becoming a mainstay in the standard
                      of care for cancer patients. Recent technological
                      advancements have significantly lowered the cost of various
                      tumor profiling approaches, broadening the reach of
                      molecular diagnostics and improving patient access to
                      precision oncology. In parallel, drug development and
                      discovery pipelines continue to evolve, driving targeted
                      therapeutic options forward. Yet, not all patients harboring
                      actionable molecular alterations respond to these
                      interventions, and existing therapies do not cover the
                      entire spectrum of potential molecular targets. In this
                      review, we examine the current suite of omics technologies
                      employed in clinical settings and underscore their roles in
                      deepening our understanding of tumor biology and optimizing
                      patient stratification for targeted treatments. We also
                      highlight relevant precision oncology trials and share our
                      own experiences using multi-omics data within a molecular
                      tumor board framework. Finally, we discuss areas for future
                      exploration aimed at propelling precision oncology to new
                      heights.},
      subtyp        = {Review Article},
      keywords     = {Humans / Precision Medicine: methods / Neoplasms: genetics
                      / Neoplasms: metabolism / Neoplasms: drug therapy /
                      Neoplasms: therapy / Genomics: methods / Proteomics: methods
                      / Multiomics / molecular profiling (Other) / patient
                      stratification (Other) / precision oncology (Other)},
      cin          = {B340 / HD01 / MU01 / DD01 / D490 / A420},
      ddc          = {570},
      cid          = {I:(DE-He78)B340-20160331 / I:(DE-He78)HD01-20160331 /
                      I:(DE-He78)MU01-20160331 / I:(DE-He78)DD01-20160331 /
                      I:(DE-He78)D490-20160331 / I:(DE-He78)A420-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40427586},
      doi          = {10.3390/biom15050693},
      url          = {https://inrepo02.dkfz.de/record/301718},
}